Most Read Articles
Jairia Dela Cruz, 05 Dec 2017
Discontinuation of aspirin may have detrimental consequences for long-term users, with a recent study reporting that cessation of use in the absence of major surgery or bleeding increases the risk of cardiovascular events.
19 Dec 2016
The prevalence of ECG for left ventricular hypertrophy (LVH) may vary depending on the criteria used across body mass index (BMI) categories in a low cardiovascular risk cohort, suggests a new study.
02 Dec 2017
The risk of congenital heart disease (CHD) Is significantly higher in foetuses conceived through in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI), according to a recent study.
01 Mar 2015
Red yeast rice extracts have been used in traditional medicine for centuries.1 In recent times, an extract from red yeast rice, Xuezhikang® (XZK), has been studied for its role in dyslipidaemia and cardiovascular disease. This review will look at some of the clinical trials that have done so.

Right ventricular end-systolic remodelling index predicts outcomes in pulmonary arterial hypertension

12 Jul 2017
Donors' organs are distributed based on clinical criteria, such as waiting times, and suitability between donors and recipients.

The right ventricular end-systolic remodelling index (RVESRI) is a simple and good prognostic marker of outcomes in patients with pulmonary arterial hypertension, a new study shows.

Univariate analysis revealed that New York Heart Association class (NYHA; hazard ratio [HR], 3.36; 95 percent CI, 2.10 to 5.38; p<0.001), serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP; HR, 1.95; 1.57 to 2.42; p<0.001), right ventricular free wall longitudinal strain (RVLS; HR, 0.63; 0.51 to 0.82; p<0.001) and RVESRI (HR, 2.05; 1.66 to 2.53; p<0.001) were all significantly associated with death, transplant or admission.

After multivariate analysis, only NYHA class (HR, 1.96; 1.14 to 3.37; p=0.01), NT-proBNP levels (HR, 1.32; 1.01 to 1.73; p=0.04) and RVESRI (HR, 1.58; 1.22 to 2.04; p=0.001) remained significant predictors of the primary endpoint of death, lung transplant or admission for heart failure.

A comparison of other indices of RV end-systolic size or transverse-to-longitudinal ratio showed that RVESRI (χ2, 62; p<0.0001) was more accurately associated with the outcome than RV end-systolic area (RVESA)/height (χ2, 52; p<0.0001), RVESA/body surface area (χ2, 48; p<0.0001) and other indices.

The final model for the primary endpoint included NYHA class, RVESRI and NT-proBNP levels (χ2, 62.2; p<0.0001). The final model for the secondary endpoint of death or lung transplant included RVESRI and NT-proBNP levels (χ2, 42.40; p<0.0001).

The study included 228 pulmonary arterial hypertension patients (mean age 49±14 years; 78 percent female). RVESRI was calculated by dividing the lateral length by the septal height, both measured from echocardiographs.

Over a mean follow-up of 3.9±2.4 years, 43 deaths, 15 transplants and 30 admissions were reported, yielding a total of 88 events for the primary endpoint and 58 for the secondary endpoint.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Dec 2017
Discontinuation of aspirin may have detrimental consequences for long-term users, with a recent study reporting that cessation of use in the absence of major surgery or bleeding increases the risk of cardiovascular events.
19 Dec 2016
The prevalence of ECG for left ventricular hypertrophy (LVH) may vary depending on the criteria used across body mass index (BMI) categories in a low cardiovascular risk cohort, suggests a new study.
02 Dec 2017
The risk of congenital heart disease (CHD) Is significantly higher in foetuses conceived through in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI), according to a recent study.
01 Mar 2015
Red yeast rice extracts have been used in traditional medicine for centuries.1 In recent times, an extract from red yeast rice, Xuezhikang® (XZK), has been studied for its role in dyslipidaemia and cardiovascular disease. This review will look at some of the clinical trials that have done so.